Target Name: CDCA4
NCBI ID: G55038
Review Report on CDCA4 Target / Biomarker Content of Review Report on CDCA4 Target / Biomarker
CDCA4
Other Name(s): CDCA4_HUMAN | hematopoietic progenitor protein | Cell division cycle-associated protein 4 | SEI-3/HEPP | Hematopoietic progenitor protein | CDCA4 variant 1 | Cell division cycle associated 4, transcript variant 1 | cell division cycle associated 4 | HEPP

CDCA4 (CDCA4_HUMAN) as a Drug Target and Biomarker: A Potential Target for the Treatment of Cancer

Abstract:
CDCA4 (CDCA4_HUMAN) is a gene that has been identified as a potential drug target and biomarker for the treatment of cancer. CDCA4 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Several studies have suggested that CDCA4 may be a useful target for cancer treatment, and ongoing research is focused on validating its potential as a drug and biomarker.

Introduction:
Cancer is a leading cause of death worldwide, and there is a significant need for new, effective treatments. The development of drug targets and biomarkers can provide new avenues for cancer research and treatment. CDCA4 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Several studies have suggested that CDCA4 may be a useful target for cancer treatment, and ongoing research is focused on validating its potential as a drug and biomarker.

CDCA4 as a Potential Drug Target:
CDCA4 has been shown to play a role in various cellular processes that are involved in cancer development. For example, several studies have shown that CDCA4 is involved in the regulation of cell cycle progression, which is a critical step in the development of cancer. In addition, CDCA4 has been shown to play a role in the regulation of apoptosis, which is a process that is involved in cell death.

CDCA4 as a Potential Biomarker:
In addition to its role in cancer development, CDCA4 has also been shown to be a potential biomarker for cancer. Several studies have shown that CDCA4 has been expressed in various types of cancer, including breast, lung, and ovarian cancer. Furthermore, several studies have shown that CDCA4 has been associated with the development of cancer, and its levels have been found to be correlated with the severity of cancer.

CDCA4 as a Potential Therapy:
CDCA4 has also been suggested as a potential therapy for cancer. Several studies have shown that CDCA4 can be downregulated in cancer cells, and this downregulation has been associated with the development of cancer. Additionally, several studies have shown that CDCA4 can be expressed in cancer cells, and that inhibition of CDCA4 has been shown to have anti-cancer effects.

Conclusion:
In conclusion, CDCA4 is a gene that has been identified as a potential drug target and biomarker for the treatment of cancer. CDCA4 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation, and has been suggested as a potential therapy for cancer. Further research is needed to fully understand the potential of CDCA4 as a drug and biomarker for the treatment of cancer.

Protein Name: Cell Division Cycle Associated 4

Functions: May participate in the regulation of cell proliferation through the E2F/RB pathway. May be involved in molecular regulation of hematopoietic stem cells and progenitor cell lineage commitment and differentiation (By similarity)

The "CDCA4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDCA4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2